Anti-Human IL-2R alpha (CD25) (Basiliximab) – Dylight® 488
Anti-Human IL-2R alpha (CD25) (Basiliximab) – Dylight® 488
Product No.: LT311
- -
- -
Product No.LT311 Clone Hu107 Target CD25 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names IL-2-RA; IL2-RA; TAC antigen; p55; CD25 Isotype Human IgG1κ Applications FC , IF , IHC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human/Rhesus Monkey/Cynomolgus Monkey Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human CD25 Product Concentration 0.2 mg/ml Formulation This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Blue Laser (493 nm) RRIDAB_2893952 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Basiliximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? IF IHC Additional Reported Applications For Relevant Conjugates ? CyTOF® WB B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Basiliximab. Basiliximab recognizes human CD25. This product is for research use only. Background CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Rα. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects. Antigen Distribution IL-2Rα is expressed on activated mature T and B lymphocytes, during early stages of thymocytes development, pre-B cells, and in activated CD4+ memory T-lymphocytes. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars References & CitationsTechnical Protocols IF  Certificate of Analysis |
Formats Available
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
